Transatlantic team-science awards to design, validate, and test interventions that prevent cancer recurrence or intercept very-early recurrent disease, with a clear line-of-sight to patient studies within two years.
Eligibility Criteria:
-
Collaborative team spanning the U.S. and UK: one Team Leader or Co-Leader must be UK-based; the other must be U.S.-based. Include up to four Team Principals, a Project Manager, and at least two Patient Advocates.
-
Independent investigators (doctoral/medical degree) at academic/medical/research institutions; for-profit/government employees may serve only as collaborators (not TL/TC/TP).
-
Minimum two participating institutions; at initial appointment, no more than one key personnel (TL/TC/TP) per institution and no more than two from affiliated institutions.
-
Early-career investigators may participate but cannot serve as TL/TC/TP; TL+TC commit ≥20% combined effort; each TP commits ≥5% effort.
-
Projects must be preclinical or later and targeted to deliver an intervention into a clinical study within two years of project start.
Funding Details:
-
Awards from USD 1,000,000 to USD 4,000,000 total for 1–4 years (up to USD 8,000,000 total program funds). Up to 10% indirect costs allowed; no indirects on UK activities.
-
Allowable: salaries/benefits (senior investigators up to 20% of total budget, not for UK-based seniors), early-career support, research staff, equipment/supplies, travel (including SU2C Summit), and up to USD 5,000/year for publications.
Deadline:
-
Letter of Intent: October 1, 2025.
-
Invitations issued week of November 4, 2025.
-
Full Application: January 21, 2026.
Where to Go for Further Information:
-
Apply via ProposalCentral using the SU2C–CRUK program templates,
-
Inquiries to [email protected].